Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-470-5 | CAS number: 2440-22-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Carcinogenicity
Administrative data
Description of key information
The substance was found to be non carcinogenic in two valid feeding studies in rats (Hunter 1981) and mice (Gfeller 1981).
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1972-02-24 to 1975-04-02
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD guideline 452 (chronic toxicity study)
- GLP compliance:
- no
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): TK 10047
- Physical state: pale yellow powder - Species:
- rat
- Strain:
- CF-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Carworth Europe, England
- Age at study initiation: 25 days old
- Weight at study initiation: individual body weights are reported.
- Fasting period before study: not reported
- Housing: the rats were housed five to a cage (unless the number was reduced by mortality), in suspended metal cages fitted with wlre-mesh floors
- Diet and water (e.g. ad libitum): free access to tap water and to quantities of powdered laboratory rat food, Spratt's Laboratory Animals Diet No. 2.
- Acclimation period: 8 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21
- Humidity (%): 55
- Air changes (per hr): not reported
- Photoperiod (hrs dark / hrs light): 12 - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- REPARATION OF DOSING SOLUTIONS:
- A premix containing 20000 ppm was prepared each week, and from this the different dietary concentrations were obtained by direct dilution with further quantities of diet. Homogeneity was achieved by mixing for ten minutes in a rotary double-cone blender; all diets were stored until use in heat-sealed, opaque polythene bags. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of the diet fed to the rats have been analysed for their content of TK 10 047 by spectrophotometry. The estimated relative reproducibility of this method is - 10% or better. Within the limits of error of sampling technique and of the analytical method, there was good correspondence between the concentrations found in the diets and the nominal values.
- Duration of treatment / exposure:
- 104 weeks
- Frequency of treatment:
- daily
- Post exposure period:
- none
- Remarks:
- Doses / Concentrations:
4 and 6 mg/kg bw ; 14 and 17 mg/kg bw0; 47 and 58 mg/kg bw; 142 and 169 mg/kg bw for males and females, respectively
Basis:
actual ingested - Dose / conc.:
- 100 ppm (nominal)
- Dose / conc.:
- 300 ppm (nominal)
- Dose / conc.:
- 1 000 ppm (nominal)
- Dose / conc.:
- 3 000 ppm (nominal)
- No. of animals per sex per dose:
- 50
- Control animals:
- yes, plain diet
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: yes
All rats were examined daily; all signs of ill-health and toxicity, together with any behavioural changes, were recorded on the so-called Case History Sheet. Detailed descriptions were made of any skin lesions, cataracts or palpable growths, together with the progression or regression of such lesions.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly for first 12 weeks, and at 4 week intervals thereafter
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: assessed in the first instance by inspection of the water bottles
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Before treatment commenced, and after 13, 26, 52, 75 and 102 weeks
- Dose groups that were examined: control and group 3
HAEMATOLOGY: Yes
- Time schedule for collection of blood:After 13, 26, 52, 78 and 102 weeks of treatment
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: 10 animals/sex from control group and group 5
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: After 13, 26, 52, 78 and 102 weeks of treatment
- Animals fasted: No data
- How many animals: 10 animals/sex from control group and group 5
URINALYSIS: Yes
- Time schedule for collection of urine: After 13, 26, 52, 78 and 103 weeks of treatment
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- ROSS PATHOLOGY: Yes
All superficial tissues, including the urinogenital orifices and tail, each pinna, orbit and external auditory meatus, were examined visually and by palpation, for distortion, swelling, or other evidence of tumour formation; similar attention was given to the mammary tracts and the cervical subcutaneous structures. The nares, buccal cavity, tongue, pharynx and auditory region were then examined, and the cranial roof removed to allow observation of the brain, pituitary gland and cranial nerves . After ventral mid-line incision and skin reflection, all subcutaneous tissues were examined, including regional lymph nodes, mammary and salivary glands . The abdominal viscera were examined before and after removal. The urinary bladder, from all rats dying or killed after 52 weeks of treatment, was briefly distended with fixative in situ, then removed, opened and examined
under low-power magnification. Stomach and caecum were incised and the mucosae scrutinised. The condition of the thoracic viscera was noted, with due attention to the thymus and lymph nodes; the heart was incised and each chamber examined. The oesophagus, intestines, and uterus were incised to expose the mucosae and subjected to visual appraisal in toto. The lungs were remoyed and all pleural surfaces examined under
suitable illumination, while the liver and kidneys were sectioned at intervals of a few millimetres; any lesion suggestive of neoplasia was noted, including details of location, size and multiplicity. Any abnormalities in the appearance and size of the gonads, adrenals, thyroids, intra-abdominal lymph nodes and accessory reproductive organs were recorded. Any evidence of adhesion, invasion or other interaction between presumptive neoplasia and the adjacent structures was noted.
HISTOPATHOLOGY: Yes
(all macroscopically observed lesions suggestive of neoplasia, for every animal; all macroscopically abnormal tissues from decedents in an attempt to ascertain cause of death; 10 rats of each sex from control and 3000 ppm killed at 104 weeks). The following organs were fixed and preserved: adrenals, aorta, brain (cerebrum,cerebellum and pons), caecum, colon, duodenum, eyes, femur, heart, ileum, jejunum, kidneys, liver, lungs, lymph nodes (cervical and mesenteric), optic nerve, ovaries, pancreas, pituitary, prostate, rectum, sciatic nerve, skeletal muscle, skin, spinal cord, stomach (cardiac, fundus and pylorus), testes, thymus, thyroid, urinary bladder, uterus, spleen
All nodules, tissue masses and otherwise macroscopically abnormal tissues were routinely preserved and processed along with samples of adjacent tissue where appropriate. - Other examinations:
- none
- Statistics:
- Student's 't' test was employed to assess the significance of intergroup differences where the data suggested a treatment related response . Differences in tumour incidence were compared by a 2 x 2 contingency test used as a one tailed test, computing the exact probability of the observed tumour distribution occurring or one which is more extreme.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- effects observed, treatment-related
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- See repeated-dose part.
- Relevance of carcinogenic effects / potential:
- No carcinogenic potential was observed in rats.
- Dose descriptor:
- NOEL
- Effect level:
- >= 3 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: 3000 ppm corresponds to 142 and 169 mg/kg bw/d for males and females, respectively.
- Remarks on result:
- other: absence of carcinogenicity
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- Critical effects observed:
- no
- Conclusions:
- No indication of carcinogenicity was observed upon chronic feed application.
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From Jul 27, 1978 to Sep 10, 1981
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 451 (Carcinogenicity Studies)
- Deviations:
- yes
- Remarks:
- hematology, urinalysis, and clinical chemistry paramters not examined
- GLP compliance:
- no
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): TK 10047
- Physical state: solid
- Lot/Batch No.: EN 71000 - Species:
- mouse
- Strain:
- other: Tif MAGF (SPF)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Animal Production Stein, CIBA-GEIGY LTD.
- Age at study initiation: Approx. 4 weeks
- Weight at study initiation: 21.7 - 22.3, males; 20.4 - 21.0, females
- Housing: housed in groups of 5 in Macrolon cages type 3 with standardised granulated soft wood bedding
- Diet (e.g. ad libitum): pelleted, certified standard Nafag No. 890 tox diet ad libitum
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2
- Humidity (%): 55 +/- 10
- Air changes (per hr): 15 - 17
- Photoperiod (hrs dark / hrs light): 14/10
IN-LIFE DATES: From: July 27, 1978 To: Aug 6, 1980 - Route of administration:
- oral: feed
- Type of inhalation exposure (if applicable):
- not specified
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
-TK 10047 was weighed on a calibrated mettler balance. The pulverised food was then homogeneously mixed with the appropriate concentrations of the compound and 30% water was added before pelleting to ensure the necessary pellet quality. The pellets were subsequently airdried. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Prior to the initiation of the study pretest feed samples were analysed for concentration and stability of the test material. The same was undertaken with the food batches applied during the test. These analyses were carried out in the Analytical Laboratories of the Plastics and Additives Division of CIBA-GEIGY LTD., Basle/Switzerland.
- Duration of treatment / exposure:
- 24 months
- Frequency of treatment:
- daily
- Post exposure period:
- not reported
- Dose / conc.:
- 5 ppm (nominal)
- Dose / conc.:
- 50 ppm (nominal)
- Dose / conc.:
- 500 ppm (nominal)
- No. of animals per sex per dose:
- 50
- Control animals:
- yes, plain diet
- Details on study design:
- Animal allocation random
- Positive control:
- None
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: weekly for 3 months, then monthly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
At the end of the test period all control and test animals which survived were bled under ether anaesthesia and subjected to detailed autopsy. Liver, adrenals, brain, heart, kidneys and gonads were weighed. These and the following organs and tissues were preserved in 10 % neutral
formalin:
brain (cerebrum, cerebellum, brainstem), eyes, pituitary, heart, thyroid, aorta, lung, spleen, lymph nodes, peripheral nerve, stomach, small and large intestine, adrenal glands, pancreas, liver, kidneys, urinary bladder, ovaries, testes, prostate, epididymis, uterus, skin (mammary area), organs and tisues showing macroscopical changes - Statistics:
- For each time point and parameter a uni-variate statistical analysis was conducted. Due to the routine manner of the analysis system, parameter free methods were applied. Each treated group was compared to the control group in respect of dispersion and displacement. In addition a trend test was applied considering all groups. Survival analysis was performed by the generalised Wilcoxon Test (Breslow 1970) and the generalised Savage Test (Mantel-Cox 1966). The Mantel-Cox and Breslow Tests differ in the way they weight observations. The Breslow Test gives greater weight to early observations, and is less sensitive to late events which occur when few animals on the study remain alive. Both tests are valid in large samples whether the censoring patterns (moribund sacrifice of interim sacrifice) are equal or unequal.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Relevance of carcinogenic effects / potential:
- The substance has no carcinogenic potential in mice.
- Dose descriptor:
- NOEL
- Effect level:
- 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: corresponds to 62- 64 mg/kg bw/d
- Remarks on result:
- other: absence of carcinogenic properties
- Critical effects observed:
- no
- Conclusions:
- The substance was not carcinogenic in mice upon feed application.
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- chronic
- Species:
- mouse
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is considered to be not classified as a carcinogen under Regulation (EC) No. 1272/2008.
Additional information
The carcinogenic potential was investigated in two feeding studies. The study in mice (Gfeller, 1981) is chosen as key study as it was specifically designed as a carcinogenicity study. Its procedure is equivalent to the OECD testing guidline 451, which was published a few months prior to finalization of that study. Its performance was supervised by the internal quality assurance unit which is certified in the study report.
Specifically, 400 MAGf (SPF) mice (50 male and 50 female per dose group) were treated at dose level of 0, 5, 50 or 500 ppm per day for 24 months. No clinical symptoms and no substance-related mortality were observed. A mean daily intake of 500 ppm (corresponding to 62-64 mg/kg bw) did not produce inflammatory, degenerative, proliferative or neoplastic lesions and was considered to be the NOEL.
The study in rats (Hunter et al, 1981) was designed as a chronic feeding study in rats (OECD testing guideline 452), but in regard to the number of animals and mortality, it is similarly suitable to assess the endpoint of carcinogenicity. Due to the overall low toxicity of this substance, high doses were tested. No indication of an increased tumour incidence or preneoplastic lesions were recorded.
Specifically, a total of 500 CFY rats (50 male and 50 female per dose group) were treated with the test article in the diet, at dose levels of 0, 100, 300, 1000 and 3000 ppm in the diet per day for 104 weeks. No clinical symptoms and no substance-related mortality were observed. At 3000 ppm a small reduction of body weight gain during the second year of treatment and slightly reduced food intake among females during the period 53 to 80 weeks of treatment were observed.
The findings are consistent with a life-time feeding study in mice for which only limited details are reported (Neukomm,1961).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
